Across TCGA pan-cancer cohorts, IGKV1D-17 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of IGKV1D-17’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where IGKV1D-17 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGKV1D-17 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
LSCC and CCRCC are the cancer types where IGKV1D-17 tumor–normal differential expression is most reproducible.